The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What patients with AML benefit from therapy with checkpoint inhibitors?

Jul 8, 2020

During the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Acute Leukaemia meeting, the AML Hub was pleased to speak to Naval Daver, MD Anderson Cancer Center, Houston, US. In this video, Naval Daver discusses the types of patients with AML that can benefit from therapy with checkpoint inhibitors.

What patients with AML benefit from therapy with checkpoint inhibitors?

Naval Daver describes data from studies that demonstrate that subsets of patients benefit from therapy with checkpoint inhibitors. He details the mechanism of action and discusses the patient characteristics and response rates to immunotherapies, including PD1/PDL1 inhibitors, bispecific antibodies, CAR T-cell therapies, and the most recent macrophage antibodies, such as CD47.